Senator Susan Collins of Maine announced Tuesday that the State Department will restore funding to GAVI, the Vaccine Alliance, a global humanitarian organization that distributes vaccines to low-income countries. The Trump administration had previously halted contributions to the program.
Collins stated that State Department officials committed to providing the full $600 million contribution after her recent advocacy efforts. GAVI operates in nearly 80 countries, delivering vaccines against diseases including measles, polio, and pneumonia to populations with limited healthcare access.
The funding pause reflected broader Trump administration skepticism toward international health organizations and multilateral commitments. The administration has questioned spending on global health initiatives, viewing some international contributions as inefficient uses of American taxpayer money.
Collins, a centrist Republican who frequently breaks with her party on foreign aid and humanitarian issues, pressed State Department leadership to reverse the decision. Her intervention highlights ongoing tension within the GOP between isolationist-leaning Trump appointees and establishment Republicans who support traditional international engagement.
GAVI's work addresses infectious disease outbreaks before they reach American shores, a public health argument that resonates with moderate Republicans. The organization has vaccinated over 900 million children since its founding in 2000, preventing millions of deaths across developing nations.
The reinstatement carries political weight beyond vaccines. It signals the Trump administration may be willing to negotiate on international spending when faced with sustained pressure from senior GOP lawmakers. Collins serves on the Senate Appropriations Committee, giving her leverage over budget allocations.
However, the episode underscores the fragility of international health funding under Republican control. Programs remain vulnerable to sudden freezes based on administration ideology rather than epidemiological need. Collins' success in this instance may not guarantee similar outcomes for other global health initiatives facing scrutiny from Trump officials.